These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33987715)

  • 21. Molecular and clinical features of K
    Hashimoto Y; Dateki S; Hirose M; Satomura K; Sawada H; Mizuno H; Sugihara S; Maruyama K; Urakami T; Sugawara H; Shirai K; Yorifuji T
    Pediatr Diabetes; 2017 Nov; 18(7):532-539. PubMed ID: 27681997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with the KCNJ11/S225T, del226-232 mutation.
    Battaglia D; Lin YW; Brogna C; Crinò A; Grasso V; Mozzi AF; Russo L; Spera S; Colombo C; Ricci S; Nichols CG; Mercuri E; Barbetti F
    Pediatr Diabetes; 2012 Dec; 13(8):656-60. PubMed ID: 22694282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.
    Kim MS; Kim SY; Kim GH; Yoo HW; Lee DW; Lee DY
    J Korean Med Sci; 2007 Aug; 22(4):616-20. PubMed ID: 17728498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Postnatal Use of Glibenclamide in Permanent Neonatal Diabetes Secondary to Antenatally Diagnosed KJCN11 Mutation.
    Walton-Betancourth S; Ashford J; Beardsall K; Gooding N; Gurnell EM; Hendriks E; Hysted H; Lee J; Thankamony A; Tseretopoulou X; Win M; Williams RM
    Horm Res Paediatr; 2022; 95(5):476-483. PubMed ID: 35817008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control.
    Stanik J; Dankovcikova A; Barak L; Skopkova M; Palko M; Divinec J; Klimes I; Gasperikova D
    Diabet Med; 2018 Mar; 35(3):386-391. PubMed ID: 29278452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glibenclamide for neonatal diabetes.
    Kochar IP; Jindal R
    Indian Pediatr; 2013 Apr; 50(4):428-9. PubMed ID: 23665609
    [No Abstract]   [Full Text] [Related]  

  • 27. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
    Mancioppi V; Pozzi E; Zanetta S; Missineo A; Savastio S; Barbetti F; Mellone S; Giordano M; Rabbone I
    Front Endocrinol (Lausanne); 2023; 14():1143736. PubMed ID: 37251668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transition from insulin to glyburide in a 4-month-old girl with neonatal diabetes mellitus caused by a mutation in KCNJ11.
    Chan YM; Laffel LM
    Pediatr Diabetes; 2007 Aug; 8(4):235-8. PubMed ID: 17659066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas.
    Dupont J; Pereira C; Medeira A; Duarte R; Ellard S; Sampaio L
    J Pediatr Endocrinol Metab; 2012; 25(3-4):367-70. PubMed ID: 22768671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.
    Zung A; Glaser B; Nimri R; Zadik Z
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5504-7. PubMed ID: 15531505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Personalized precision medicine in extreme preterm infants with transient neonatal diabetes mellitus.
    Kylat RI; Senguttuvan R; Bader MY
    J Pediatr Endocrinol Metab; 2017 May; 30(5):593-596. PubMed ID: 28350539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personalized medicine switching from insulin to sulfonylurea in permanent neonatal diabetes mellitus dictated by a novel activating ABCC8 mutation.
    Mak CM; Lee CY; Lam CW; Siu WK; Hung VC; Chan AY
    Diagn Mol Pathol; 2012 Mar; 21(1):56-9. PubMed ID: 22306677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transfer from insulin to sulfonylurea treatment in a chinese patient with permanent neonatal diabetes mellitus due to a KCNJ11 R201H mutation.
    Xiao X; Wang T; Li W; Song H; Gong C; Diao C; Yu M; Yuan T; Zhang Y; Sun X; Zhang Q; Lu K; Wang H; Schmitz O; Hansen T
    Horm Metab Res; 2009 Jul; 41(7):580-2. PubMed ID: 19247925
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation.
    Wambach JA; Marshall BA; Koster JC; White NH; Nichols CG
    Pediatr Diabetes; 2010 Jun; 11(4):286-8. PubMed ID: 19656320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
    Al-Mahdi M; Al Mutair A; Al Balwi M; Hussain K
    Ann Saudi Med; 2010; 30(2):162-4. PubMed ID: 20220270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
    Shimomura K; Hörster F; de Wet H; Flanagan SE; Ellard S; Hattersley AT; Wolf NI; Ashcroft F; Ebinger F
    Neurology; 2007 Sep; 69(13):1342-9. PubMed ID: 17652641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sulfonylurea-responsive diabetes in childhood.
    Landau Z; Wainstein J; Hanukoglu A; Tuval M; Lavie J; Glaser B
    J Pediatr; 2007 May; 150(5):553-5. PubMed ID: 17452235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes.
    Myngheer N; Allegaert K; Hattersley A; McDonald T; Kramer H; Ashcroft FM; Verhaeghe J; Mathieu C; Casteels K
    Diabetes Care; 2014 Dec; 37(12):3333-5. PubMed ID: 25231897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neonatal diabetes mellitus due to L233F mutation in the KCNJ11 gene.
    Joshi R; Phatarpekar A
    World J Pediatr; 2011 Nov; 7(4):371-2. PubMed ID: 21210267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE; Babiker T; Thomas NJ; Shepherd MH; Ellard S; Klimes I; Szopa M; Polak M; Iafusco D; Hattersley AT; Njølstad PR;
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.